Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release…
Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release Capsules USP
- Published
- 13 May 2026
- Units affected
- 165,761 90-count bottles
- Agency
- FDA
- Country
- United States
The hazard
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
Duloxetine Delayed-Release Capsules USP, 60mg, Rx Only, 90-count bottle, Mfr. by Towa Pharmaceutical Eurpoe S.L., Martorelles, (Barcelona), Spain, Dist. by. Breckenridge Pharmaceutical, Inc., Berkely Heights, NJ 07922, NDC 51991-748-90.
- Brand / company
- Breckenridge Pharmaceutical, Inc.
- Codes / lots
- Lot: 241069C, Exp 05/31/2027
- Distribution
- Nationwide in the USA
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 13 May 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.